Tissue tumor mutation burden (tTMB) has been under study for some time as a biomarker that could predict which patients are most likely to respond to immunotherapy. In June, it was approved by the US ...
Camrelizumab combined with FOLFOX as neoadjuvant therapy for resectable locally advanced gastric and gastroesophageal junction adenocarcinoma. PILGRIM: Phase III clinical trial in evaluating the role ...
Predictive cytokine biomarkers for immune-related adverse events associated with immune checkpoint inhibitor therapy in Hodgkin lymphoma. Biomarkers Specificity (95% CI) Positive Likelihood Ratio (95% ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results